Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.evoqremedies.com | |
Market Cap | 16.73 Cr. | |
Enterprise Value(EV) | 18.00 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 1.19 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 10.33 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 70.78 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 18.22 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 0.67 | Calculated using Price: 12.30 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.36 Cr. | 13,600,000 Shares |
FaceValue | 10 | |
About EVOQ Remedies Ltd. | ||
The company specializes in offering quality Pharmaceuticals Raw Material products, Excipients, and Bulk Drugs at an affordable prices. |
1 Day |
|
|
1 Week |
|
+1.65% |
1 Month |
|
-3.53% |
3 Month |
|
-14.46% |
6 Month |
|
-5.38% |
1 Year |
|
-20.13% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
5 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 49.78 | 1.34 | 186.89 | 9.13 | 6.75 | |
Return on Capital Employed (%) | 68.94 | 2.69 | 246.90 | 9.12 | 6.96 | |
Return on Assets (%) | 0.52 | 0.01 | 10.45 | 5.27 | 4.75 |
Particulars | 6 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 0 | 0 | 1 | 23 | 25 | 25 | |
Non Curr. Liab. | 0 | ||||||
Curr. Liab. | 2 | 6 | 7 | 10 | 10 | 6 | |
Minority Int. | |||||||
Equity & Liab. | 2 | 6 | 8 | 33 | 35 | 31 | |
Non Curr. Assets | 0 | 0 | |||||
Curr. Assets | 2 | 6 | 8 | 33 | 35 | 31 | |
Misc. Exp. not W/O | |||||||
Total Assets | 2 | 6 | 8 | 33 | 35 | 31 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Net Sales | 3 | 9 | 10 | 17 | 20 | |
Other Income | 6 | |||||
Total Income | 3 | 9 | 10 | 17 | 26 | |
Total Expenditure | -3 | -9 | -9 | -15 | -24 | |
PBIDT | 0 | 1 | 1 | 2 | ||
Interest | ||||||
Depreciation | ||||||
Taxation | 0 | 0 | -1 | |||
Exceptional Items | ||||||
PAT | 0 | 1 | 1 | 2 | ||
Adjusted EPS | 10 | 1 | 1 |
Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | 0 | -26 | -4 | |
Cash Fr. Inv. | 0 | |||||
Cash Fr. Finan. | 29 | 1 | ||||
Net Change | 0 | 0 | 0 | 3 | -3 | |
Cash & Cash Eqvt | 0 | 0 | 3 | 0 |
Fri, 10 Nov 2023
Submission Of Unaudited Financial Results For The Half Year Ended On 30Th September 2023 Along With Limited Review Report Submission of Unaudited Financial Results for the Half Year ended on 30th September 2023 along with Limited review Report. |
Fri, 10 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 10Th November 2023 Pursuant to second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of the Company in their meeting held today i.e. On 10th November 2023 at the Registered Office of the Company situated at A-1106 Empire Business Hub Near AUDA Water Tank Science City Road Sola Ahmedabad - 380 060 which commenced at 5:00 P.M and concluded at 6:00 P.M. has considered and approved Unaudited Financial Results for the Half Year ended on 30th September 2023 along with Limited Review Report. |
Wed, 08 Nov 2023
Board Meeting Outcome for Intimation Of Board Meeting To Be Held On Friday 10Th November 2023 Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of the Board of Directors of the Company held today i.e. Wednesday 8th November 2023 at 5:00 P.M. at A-1106 Empire Business Hub Near AUDA Water Tank Science City Road Sola Ahmedabad - 380 060 it has been stands postponed to 10th November 2023 at the same time and venue inter-alia to discuss consider and approve inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter and half year ended on 30th September 2023 along with Limited Review Report. |
Thu, 30 Nov 2023 |
|
|
|
|
|